104 related articles for article (PubMed ID: 16549120)
1. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Yakupoglu YK; Buell JF; Woodle S; Kahan BD
Transplant Proc; 2006 Mar; 38(2):358-61. PubMed ID: 16549120
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
Langer RM; Kahan BD
Transplantation; 2003 Jul; 76(2):318-23. PubMed ID: 12883185
[TBL] [Abstract][Full Text] [Related]
3. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
Mathew T; Kreis H; Friend P
Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
5. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
Benavides CA; Pollard VB; Mauiyyedi S; Podder H; Knight R; Kahan BD
Transplantation; 2007 Jul; 84(1):83-8. PubMed ID: 17627242
[TBL] [Abstract][Full Text] [Related]
6. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
Kahan BD; Podbielski J; Schoenberg L
Transplant Proc; 2006 Nov; 38(9):2842-6. PubMed ID: 17112844
[TBL] [Abstract][Full Text] [Related]
7. Post-kidney transplant surgical complications under new immunosuppressive regimens.
Burgos FJ; Pascual J; Quicios C; Marcen R; Fernández A; López Fando L; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2445-7. PubMed ID: 17097962
[TBL] [Abstract][Full Text] [Related]
8. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
Lisik W; Schoenberg L; Lasky RE; Kahan BD
Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
[TBL] [Abstract][Full Text] [Related]
9. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
[TBL] [Abstract][Full Text] [Related]
10. Conversion to sirolimus in renal transplant patients with tumors.
Sánchez-Fructuoso A; Conesa J; Perez Flores I; Ridao N; Calvo N; Prats D; Rodríguez A; Barrientos A
Transplant Proc; 2006 Oct; 38(8):2451-2. PubMed ID: 17097964
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
13. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
14. Conversion to sirolimus in posttransplant renal neoplasms.
Lopez V; Gutierrez C; Cabello M; Burgos D; Sola E; Gonzalez-Molina M
Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
[TBL] [Abstract][Full Text] [Related]
15. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
[TBL] [Abstract][Full Text] [Related]
16. Conversion to sirolimus in pediatric renal transplantation recipients.
Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
[TBL] [Abstract][Full Text] [Related]
17. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure.
Romagnoli J; Citterio F; Favi E; Salerno MP; Tondolo V; Spagnoletti G; Renna R; Castagneto M
Transplant Proc; 2007; 39(6):1823-6. PubMed ID: 17692622
[TBL] [Abstract][Full Text] [Related]
18. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
